Compare CDW & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDW | NBIX |
|---|---|---|
| Founded | 1984 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 13.2B |
| IPO Year | 2013 | 1996 |
| Metric | CDW | NBIX |
|---|---|---|
| Price | $114.54 | $156.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 22 |
| Target Price | $164.88 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 2.2M | 1.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | 1.38 | ★ 41.95 |
| EPS | 1.82 | ★ 1.91 |
| Revenue | ★ $10,768,600,000.00 | $161,626,000.00 |
| Revenue This Year | $4.08 | $24.73 |
| Revenue Next Year | $4.01 | $13.14 |
| P/E Ratio | ★ $62.85 | $81.80 |
| Revenue Growth | 6.32 | ★ 977.51 |
| 52 Week Low | $97.12 | $121.42 |
| 52 Week High | $183.91 | $162.39 |
| Indicator | CDW | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 47.94 | 67.61 |
| Support Level | $97.12 | $133.96 |
| Resistance Level | $125.24 | $160.08 |
| Average True Range (ATR) | 3.97 | 3.96 |
| MACD | 1.21 | -0.33 |
| Stochastic Oscillator | 82.14 | 51.83 |
CDW Corp is a multi-brand provider of information technology (IT) solutions to businesses, government, education, and healthcare customers in the United States, the United Kingdom, and Canada. The company's offerings range from hardware and software products to integrated IT solutions and services, including on-premise and cloud capabilities across hybrid infrastructure, digital experience, and security. Its reportable segments are Corporate, Small Business, Public, and Other. The Corporate and Small Business segments serve US private sector business customers, while the Public segment consists of government agencies and education and healthcare institutions in the US. The Corporate segment generates the majority of its revenue in the United States.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.